Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHG Bright Health Group	$6.65 +2.4%	$6.78	$4.94 ▼ $82.40	$53.04M	0.93	72,717 shs	13,443 shs
IPHA Innate Pharma	$2.10 -0.2%	$1.98	$1.29 ▼ $3.51	$193.12M	0.22	101,541 shs	23,474 shs
LYEL Lyell Immunopharma	$11.28 +2.9%	$10.33	$7.65 ▼ $32.00	$216.69M	-0.19	81,989 shs	12,546 shs
TNYA Tenaya Therapeutics	$1.10 +1.9%	$0.78	$0.36 ▼ $4.01	$179.28M	3.01	2.97 million shs	1.85 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHG Bright Health Group	-0.28%	-1.22%	-4.14%	-4.72%	+32.45%
IPHA Innate Pharma	-6.49%	-9.61%	+1.03%	-3.69%	-7.16%
LYEL Lyell Immunopharma	-0.09%	+1.20%	-11.76%	+33.66%	-65.53%
TNYA Tenaya Therapeutics	+0.93%	-8.47%	+29.62%	+144.51%	-62.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHG Bright Health Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	2.4174 of 5 stars	3.7	2.0	0.0	0.0	3.3	1.7	0.0
LYEL Lyell Immunopharma	3.7717 of 5 stars	2.8	5.0	0.0	0.0	3.3	4.2	1.3
TNYA Tenaya Therapeutics	3.1346 of 5 stars	3.5	1.0	0.0	0.0	3.5	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHG Bright Health Group	0.00	N/A	N/A	N/A
IPHA Innate Pharma	3.33	Buy	$11.00	425.06% Upside
LYEL Lyell Immunopharma	1.50	Reduce	$15.00	32.98% Upside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	468.18% Upside

Current Analyst Ratings Breakdown

Latest BHG, LYEL, IPHA, and TNYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
8/7/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/28/2025	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/24/2025	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHG Bright Health Group	$2.76B	0.02	N/A	N/A	($25.47) per share	-0.26
IPHA Innate Pharma	$21.77M	8.87	N/A	N/A	$0.11 per share	19.05
LYEL Lyell Immunopharma	$60K	3,611.48	N/A	N/A	$15.56 per share	0.72
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$0.61 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHG Bright Health Group	-$1.46B	-$208.73	N/A	N/A	N/A	-85.40%	N/A	-10.26%	N/A
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
LYEL Lyell Immunopharma	-$342.99M	-$24.29	N/A	N/A	N/A	-552,328.31%	-85.58%	-68.85%	11/6/2025 (Estimated)
TNYA Tenaya Therapeutics	-$111.13M	-$0.96	N/A	N/A	N/A	N/A	-93.83%	-75.66%	11/5/2025 (Estimated)

Latest BHG, LYEL, IPHA, and TNYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	LYEL Lyell Immunopharma	-$3.80	-$2.89	+$0.91	-$2.89	$0.00 million	$0.01 million
8/6/2025	Q2 2025	TNYA Tenaya Therapeutics	-$0.20	-$0.14	+$0.06	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHG Bright Health Group	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHG Bright Health Group	N/A	1.04	1.04
IPHA Innate Pharma	2.52	2.60	2.60
LYEL Lyell Immunopharma	N/A	7.65	7.65
TNYA Tenaya Therapeutics	N/A	6.00	6.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHG Bright Health Group	N/A
IPHA Innate Pharma	0.16%
LYEL Lyell Immunopharma	66.05%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
BHG Bright Health Group	58.40%
IPHA Innate Pharma	31.89%
LYEL Lyell Immunopharma	22.30%
TNYA Tenaya Therapeutics	48.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHG Bright Health Group	2,840	7.98 million	3.32 million	Not Optionable
IPHA Innate Pharma	220	92.18 million	62.79 million	Not Optionable
LYEL Lyell Immunopharma	270	19.21 million	14.93 million	Optionable
TNYA Tenaya Therapeutics	110	162.98 million	83.69 million	Optionable

BHG, LYEL, IPHA, and TNYA Headlines

Recent News About These Companies

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Recommendation of "Buy" from Brokerages

August 26 at 3:15 AM | americanbankingnews.com

Faraz Ali Sells 14,533 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock

August 20, 2025 | marketbeat.com

Tenaya Therapeutics Reports Q2 2025 Financial Results

August 14, 2025 | tipranks.com

What is Leerink Partnrs' Estimate for TNYA FY2025 Earnings?

August 11, 2025 | marketbeat.com

Q3 EPS Estimate for Tenaya Therapeutics Lifted by Analyst

August 11, 2025 | marketbeat.com

Wall Street Zen Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Hold

August 10, 2025 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Given Buy Rating at Chardan Capital

August 8, 2025 | marketbeat.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 8, 2025 | globenewswire.com

Tenaya Therapeutics reports Q2 EPS (14c), consensus (19c)

August 7, 2025 | msn.com

Tenaya Therapeutics (TNYA) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Tenaya (TNYA) Q2 Loss Narrows 59%

August 7, 2025 | fool.com

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025 | globenewswire.com

Equities Analysts Offer Predictions for TNYA Q1 Earnings

August 4, 2025 | marketbeat.com

Lifesci Capital Issues Negative Outlook for TNYA Earnings

August 4, 2025 | marketbeat.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Buy" from Analysts

August 1, 2025 | marketbeat.com

Tenaya Therapeutics stock rises after positive safety reviews for heart gene therapies

July 30, 2025 | investing.com

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

July 30, 2025 | globenewswire.com

TNYA - Tenaya Therapeutics Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

TNYA - Tenaya Therapeutics Inc Trailing Returns - Morningstar

July 8, 2025 | morningstar.comM

Tenaya Therapeutics, Inc. (TNYA) Balance Sheet - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Tenaya Therapeutics, Inc. (TNYA) Cash Flow - Yahoo Finance

June 27, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHG, LYEL, IPHA, and TNYA Company Descriptions

Bright Health Group NYSE:BHG

$6.64 +0.16 (+2.39%)

As of 08/26/2025

Bright Health Group, Inc., a healthcare company, provides health insurance policies in the United States. It operates in two segments, Bright HealthCare and Consumer Care. The Consumer Care segment delivers virtual and in-person clinical care services contracts through primary care clinics. It operates managed and affiliated risk-bearing clinics within its integrated care delivery system, which included embedded pharmacy, laboratory, radiology, and population health focused specialty services. The Bright HealthCare segment offers medicare health plan products to consumers. The company was formerly known as Bright Health Inc. and changed its name to Bright Health Group, Inc. in February 2021. Bright Health Group, Inc. was incorporated in 2015 and is headquartered in Minneapolis, Minnesota.

Innate Pharma NASDAQ:IPHA

$2.08 -0.02 (-0.95%)

As of 04:00 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Lyell Immunopharma NASDAQ:LYEL

$11.28 +0.32 (+2.92%)

Closing price 04:00 PM Eastern

Extended Trading

$11.28 +0.01 (+0.04%)

As of 04:26 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Tenaya Therapeutics NASDAQ:TNYA

$1.10 +0.02 (+1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$1.10 0.00 (0.00%)

As of 06:00 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time